 | Up a level |
Journal Article
Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. S. (2020). CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann. Oncol., 31. S. S894 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Font, E. F., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. (2021). CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation. J. Thorac. Oncol., 16 (1). S. S29 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G. K., Price, T., Borghaei, H., Kato, T., Takahashi, T., Spira, A., Ramalingam, S., Besse, B., Barlesi, F., Tran, Q., Henary, H., Ngarmchamnanrith, G., Govindan, R. and Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. Pneumologie, 75. S. S38 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790